Complete gene sequencing of BRCA1 and BRCA2 genes to detect pathogenic variants associated with hereditary breast and ovarian cancer syndrome. Identifies deletions, insertions, and point mutations. Results assess lifetime cancer risk and inform screening protocols, preventive interventions, and family risk assessment. Includes genetic counseling support.

Circulating tumor DNA (ctDNA) analysis from blood sample in patients with advanced solid tumors (stage III/IV). Next-generation sequencing of 81 cancer-related genes including: EGFR, ALK, ROS1, BRAF, KRAS, NRAS, PIK3CA, HER2, MET, RET, BRCA1, BRCA2, ATM, PALB2, PTEN, TP53, and others. Identifies actionable mutations to guide targeted therapy selection and immuno-oncology treatment decisions. Not applicable for hematologic malignancies. Serial testing monitors treatment response and emerging resistance mutations.